Physician

Stefano Emili, MD

According to 2025 Medicare claims, Stefano Emili, MD (NPI: 1558319434) practices internal medicine in the Anchorage, AK market, with the plurality of this provider's patient population coming from Anchorage, AK. This provider's primary affiliated billing organization is AURORA KIDNEY LLC (NPI: 1659417137; TIN: 208306374) and primary practice location at 99504-4904.

Emili's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 488 traditional Medicare patients, billed 3,346 HCPCS/CPT codes, and received $457,186 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 5,227 prescription claims across 413 beneficiaries totaling $1,221,308 in drug costs, led by Xphozah (Tenapanor Hcl). DME data shows 1,354 claims. Open Payments data shows 14 records totaling $366. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Similarly, Part D prescription costs have changed little. In contrast, DME billing represents a smaller volume and moved from a lower plateau to a higher plateau, from $9,099 to $12,019.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	482	3,567	$382,711
2016	478	3,516	$414,329
2017	452	3,349	$423,548
2018	486	5,097	$454,660
2019	473	3,395	$473,755
2020	462	3,145	$453,998
2021	485	3,264	$563,244
2022	489	3,330	$524,719
2023	476	3,341	$436,329
2024	488	3,346	$457,186

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	243	7,420	$1,010,232
2016	250	5,371	$1,208,999
2017	247	4,977	$1,454,582
2018	261	4,840	$1,084,334
2019	376	6,094	$1,216,979
2020	402	6,314	$1,203,450
2021	402	6,335	$1,062,593
2022	384	5,399	$905,287
2023	381	4,567	$1,029,411
2024	413	5,227	$1,221,308

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	97	617	$46,380
2016	113	917	$66,399
2017	126	975	$64,432
2018	120	1,088	$74,819
2019	127	1,073	$68,041
2020	124	1,268	$68,893
2021	104	1,230	$58,900
2022	104	1,143	$44,965
2023	132	1,141	$39,427
2024	153	1,354	$43,063

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	96	723	$346
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	97	146	$111
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	107	177	$74
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	138	203	$67
90935	Hemodialysis procedure with physician evaluation	117	257	$66

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xphozah	Tenapanor Hcl	38	1,470	$138,861
Auryxia	Ferric Citrate	69	3,282	$136,384
Velphoro	Sucroferric Oxyhydroxide	55	1,748	$129,313
Trulicity	Dulaglutide	47	1,932	$62,464
Farxiga	Dapagliflozin Propanediol	39	2,850	$51,988

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	21	179	$10,140
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	N/R	21	$8,000
J7527	Everolimus, oral, 0.25 mg	N	N/R	12	$5,556
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	39	365	$4,943
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	38	275	$4,780

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	14	$366	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Stefano Emili, MD?

Tedicare shows public-source Medicare data for Stefano Emili, MD (NPI 1558319434), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Stefano Emili, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Stefano Emili, MD?

Stefano Emili, MD is linked to AURORA KIDNEY LLC (billing NPI 1659417137) in the available physician profile data.

Does Stefano Emili, MD have Open Payments data?

Stefano Emili, MD has 14 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.